Spondyloarthropathies: An independent cardiovascular risk factor?

Joint Bone Spine

Volumn 77, Issue 6, 2010, Pages 542-545

  Mathieu, Sylvain ^a   Motreff, Pascal ^a   Soubrier, Martin ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Ankylosing spondylitis; Cardiovascular morbidity; Cardiovascular mortality; Psoriatic arthritis

Indexed keywords

C REACTIVE PROTEIN; DICLOFENAC; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IBUPROFEN; NAPROXEN;

ANKYLOSING SPONDYLITIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; DISEASE CONTROL; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; SHORT SURVEY; SPONDYLOARTHROPATHY; STANDARDIZED MORTALITY RATIO;

ANTICHOLESTEREMIC AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; COMORBIDITY; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; RISK FACTORS; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; SURVIVAL RATE;

EID: 78649907560     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.05.001     Document Type: Short Survey

References (53)

1. Solomon D.H., Karlson E.W., Rimm E.B., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303-1307.
2. Maradit-Kremers H., Nicola P.J., Crowson C.S., et al. Cardiovascular death in rheumatoid arthritis. Arthritis Rheum 2005, 52:722-732.
3. Peters M.J., van Halm V.P., Voskuyl A.E., et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009, 61:1571-1579.
4. Soubrier M., Mathieu S., Dubost J.J. Atheroma and systemic lupus erythematosus. Joint Bone Spine 2007, 74:566-570.
5. Hak A.E., Karlson E.W., Feskanich D., et al. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the Nurses' Health Study. Arthritis Rheum 2009, 61:1396-1402.
6. Lautermann D., Braun J. Ankylosing spondylitis-cardiac manifestations. Clin Exp Rheumatol 2002, 20:S11-S15.
7. Vinsonneau U., Brondex A., Mansourati J., et al. Cardiovascular disease in patients with spondyloarthropathies. Joint Bone Spine 2008, 75:18-21.
8. Radford E.P., Doll R., Smith P.G. Mortality among patients with ankylosing spondylitis not given X-ray therapy. N Engl J Med 1977, 11:572-576.
9. Kaprove R.E., Little A.H., Graham D.C., et al. Ankylosing spondylitis: survival in men with and without radiotherapy. Arthritis Rheum 1980, 23:57-61.
10. Smith P.G., Doll R. Mortality among patients with ankylosing spondylitis after a single treatment course with X-rays. BMJ 1982, 13:449-460.
11. Hollan I., Saatvedt K., Almdahl S.M., et al. Spondyloarthritis: a strong predictor of early coronary artery bypass grafting. Scand J Rheumatol 2008, 37:18-22.
12. Peters M.J., Visman I., Nielen M.M., et al. Ankylosing spondylitis; a risk factor for myocardial infarction?. Ann Rheum Dis 2010, 69:579-581.
13. Wong K., Gladman D.D., Husted J., et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic I. Causes and risk of death. Arthritis Rheum 1997, 40:1868-1872.
14. Gladman D.D., Ang M., Su L., et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009, 68:1131-1135.
15. Han C., Robinson D.W., Hackett M.V., et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006, 33:2167-2172.
16. Gonzalez-Juanatey C., Llorca J., Miranda-Filloy J.A., et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:287-293.
17. Gonzalez-Juanatey C., Llorca J., Amigo-Diaz E., et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:1074-1080.
18. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Vazquez-Rodriguez T.R., et al. Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2009, 39:157-162.
19. Tam L.S., Shang Q., Li E.K., et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008, 59:1322-1331.
20. Tam L.S., Tomlinson B., Chu T.T., et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls: the role of inflammation. Rheumatology (Oxford) 2008, 47:718-723.
21. Kimhi O., Caspi D., Bornstein N.M., et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007, 36:203-209.
22. Eder L., Zisman D., Barzilai M., et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008, 35:877-882.
23. Sari I., Okan T., Akar H., et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 2006, 45:283-286.
24. van Eijk I.C., Peters M.J., Serné E.H., et al. Vascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 2009, 68:362-366.
25. Calistan M., Erdogan D., Gullu H., et al. Impaired coronary microvascular and left ventricular diastolic functions in patients with ankylosing spondylitis. Atherosclerosis 2008, 196:306-312.
26. Mathieu S., Joly H., Baron G., et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford) 2008, 47:1203-1207.
27. Choe J.Y., Lee M.Y., Rheem I., et al. No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 2008, 75:548-553.
28. Malesci D., Niglio A., Mennillo G.A., et al. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 2007, 26:710-714.
29. Gonzalez-Juanatey C., Vazquez-Rodriguez T.R., Miranda-Filloy J.A., et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009, 88:358-365.
30. Sattar N., McCarrey D.W., Capell H., et al. Explaining how " high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957-2963.
31. Buckley D.I., Fu R., Freeman M., et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the US Preventive Services Task Force. Ann Intern Med 2009, 151:483-495.
32. Divecha H., Sattar N., Rumley A., et al. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci 2005, 109:171-176.
33. Papadakis J.A., Sidiropoulos P.I., Karvounaris S.A., et al. High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity. Clin Exp Rheumatol 2009, 27:292-298.
34. Van Halm V.P., van Denderen J.C., Peters M.J., et al. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 2006, 65:1473-1477.
35. van Eijk I.C., de Vries M.K., Levels J.H., et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009, 60:1324-1330.
36. Gordon D.J., Rifkind B.M. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med 1989, 321:1311-1316.
37. Davidson M.H., Toth P.P. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol 2007, 100:n32-40.
38. Choy E., Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009, 68:460-469.
39. Sattar N., Crompton P., Cherry L., et al. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007, 56:831-839.
40. Spanakis E., Sidiropoulos P., Papadakis J., et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006, 33:2440-2446.
41. Sidiropoulos P.I., Karvounaris S.A., Boumpas D.T. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther 2008, 10:207.
42. Pereira R.M., de Carvalho J.F., Bonfá E. Metabolic syndrome in rheumatological diseases. Autoimmun Rev 2009, 8:415-419.
43. Gottlieb A.B., Dann F. Comorbidities in patients with psoriasis. Am J Med 2009, 122. 1150.e1-9.
44. Lambert J.R., Wright V. Serum uric acid levels in psoriatic arthritis. Ann Rheum Dis 1977, 36:264-267.
45. Kim S.Y., Guevara J.P., Kim K.M., et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 2010, 62:170-180.
46. Kearney P.M., Baigent C., Godwin J., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332:1302-1308.
47. McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006, 296:1633-1644.
48. Peters M.J., Symmons D.P., McCarey D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
49. Agence française de sécurité sanitaire des produits de santé. Prise en charge thérapeutique du patient dyslipidémique. 2005.
50. Pham T., Gossec L., Constantin A., et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006, 73:379-387.
51. Soubrier M., Brucker E. Le rhumatologue doit-il prescrire des statines ?. Joint Bone Spine 2010, 77:115-117.
52. van Denderen J.C., Peters M.J., van Halm V.P., et al. Statin therapy might be beneficial for patients with ankylosing spondylitis. Ann Rheum Dis 2006, 65:695-696.
53. HAS. Prise en charge des patients adultes atteints d'hypertension artérielle essentielle. 2005.